ArticleActa pharmacologica Sinica2022

Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.

Chang-Ling Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.